On March 2, 2020, CRISPR's stock opened at a price of $54. By January 2021, amid the meme stock hype, shares of CRISPR reached highs of more than $200, and the stock was looking like a fantastic buy.

Most of any gains (or lack thereof) from here will be driven by just three factors.

Drug-resistant tuberculosis remains one of the most stubborn obstacles in global infectious disease control, and a new mini ...

ERS Genomics Limited ('ERS Genomics'), the CRISPR licensing company, today announced that it has signed a non-exclusive ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

This week marks an incredible win for modern medicine. The first CRISPR-based gene therapy has just been approved for clinical use in the United Kingdom. Casegvy (Exa-cel), developed by Vertex and ...

Rockville, March 15, 2023 (GLOBE NEWSWIRE) -- Fact.MR – A Market research and competitive intelligence provider: The global CRISPR and Cas genes market expanded market size at a CAGR of 20% during the ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...